Macrolides have been regarded for many decades as having good activity and safety for the treatment of infections caused by gram-positive cocci. In general, macrolides show modest potency against *Enterobacteriaceae*. Most *Shigella* and *Salmonella* spp. pathogens display MICs of azithromycin, a macrolide antimicrobial drug, ranging from 2 mg/L to 8 mg/L ([@R1]). Despite these relatively high MICs, azithromycin is an attractive option for several reasons. It can be given once a day and attains high intracellular concentrations and sufficient concentrations in the colon of patients to inhibit *Shigella* and *Salmonella* spp. Azithromycin is recommended by the American Academy of Pediatrics for treatment of shigellosis in children ([@R2]) and by the World Health Organization as a second-line treatment for adults ([@R3]). It has also been proposed for short-course treatment of typhoid fever ([@R4]).

We recently reported an outbreak of shigellosis in Paris, France; failure of azithromycin treatment was related to emergence of plasmid-mediated resistance to macrolides ([@R5]). Resistance was related to the expression of a macrolide 2′ phosphotransferase encoded by the *mph*(A) gene. Because shigellosis remains a common gastrointestinal disease in both developing and industrialized countries, emergence of macrolide resistance may have major public health consequences.

Since the early reports by Ochiai ([@R6]) and Akiba ([@R7]) at the end of the 1950s, plasmid-mediated transfer of resistance genes between *Escherichia coli* and *Shigella* spp. has been reported in several instances ([@R8]). Therefore, we hypothesized that *E. coli* might constitute a major reservoir for macrolide resistance genes that could be subsequently transferred to *Shigella sonnei*.

Acquired resistance to macrolides may result from a variety of mechanisms of resistance, several of which have already been reported in *Enterobacteriaceae* ([@R9],[@R10]). These mechanisms include target site modification by methylases encoded by *erm* genes, in particular *erm*(A), *erm*(B), and *erm*(C). Macrolides may be inactivated by modifying enzymes first reported in *Enterobacteriaceae* ([@R11],[@R12]), e.g., esterases encoded by *ere*(A) or *ere*(B) genes or phosphotransferases encoded by *mph*(A), *mph*(B), and *mph*(D) genes. The third mechanism is acquisition of efflux pumps, *mef*(A) and *msr*(A), that have been found essentially in gram-positive organisms, although *mef*(A) has been identified in gram-negative organisms ([@R10]). All of these genes confer full cross-resistance between erythromycin and azithromycin ([@R9]). We aimed to assess the prevalence of acquired resistance to macrolides in commensal and clinical isolates of *E. coli* from various geographic origins and to characterize the mechanisms underlying E. coli resistance to macrolides.

The Study
=========

A total of 190 *E. coli* isolates were collected from 5 countries on 4 continents. Some of these isolates were obtained from populations exposed to low antimicrobial selective pressure; 45 commensal isolates were from feces of healthy Wayampi Amerindians in French Guiana, 20 from feces of children living in a remote village of Senegal, and 49 from feces of healthy nurses working in a hospital in Paris. Other isolates were obtained from populations having received multiple antimicrobial drug treatments; 29 isolates were from feces of children from Niger hosted in a center for nutritional rehabilitation, and 47 isolates were producers of extended-spectrum β-lactamase (ESBL) obtained from various clinical samples in hospitalized patients in Vietnam (n = 37) and France (Hospital of Caen) (n = 10).

Susceptibility to 16 antimicrobial drugs was determined by the disk-diffusion method. MICs of erythromycin were determined by the agar dilution technique, and ESBLs were detected by the double-disk synergy test, as recommended by the French Society for Microbiology ([www.sfm.asso.fr](http://www.sfm.asso.fr)).

*E. coli* isolates from French Guiana, Senegal, and Paris were susceptible to quinolones, gentamicin, and third-generation cephalosporins. Resistance to amoxicillin-ticarcillin (by penicillinase production) was detected for 22.2%, 20.4%, and 40.0% of the isolates obtained from nurses in Guiana, Paris, and Senegal, respectively. Coresistance to amoxicillin and cotrimoxazole was found for 13%, 14%, and 35% of isolates, respectively.

Multidrug-resistant isolates were commonly obtained from Niger natives; 34.4% were resistant to both cefotaxime (mostly by ESBL production) and ciprofloxacin, and 58.6% to gentamicin. ESBL producers from Vietnam and Caen hospital displayed resistance to ciprofloxacin for 86.5% and 60.0% and resistance to gentamicin for 86.4% and 50.0% of isolates, respectively. MICs of erythromycin ranged from 16 mg/L to \>1,024 mg/L ([Table 1](#T1){ref-type="table"}; Figure). Distribution of MICs of erythromycin was bimodal; mode = 64 mg/L for 1 population with low MICs and [\>]{.ul}1,024 mg/L for the other population with high MICs ([Figure](#F1){ref-type="fig"}).

###### MICs of erythromycin and distribution of macrolide resistance genes among 190 *Escherichia coli* isolates from 5 countries\*

  *E. coli* origin (no. isolates)                                             MIC of erythromycin, mg/L         Gene, no. (%)†                           
  --------------------------------------------------------------------------- --------------------------- ----- ---------------- -- ---------- --------- --------
  French Guiana, Amerindians (45)                                             32--1,024                   64    128                 0          1 (2)     0
  Senegal, remote village (20)                                                64--128                     128   128                 0          0         0
  Niger, children (29)                                                        64--\>1,024                 256   \>1,024             0          9 (31)    0
  France, healthy nurses (49)                                                 16--256                     64    128                 0          2 (4)     1 (2)
  France, ESBL isolates (10)                                                  64--1,024                   128   1,024               0          3 (30)    1 (10)
  Vietnam, ESBL isolates (37)                                                 32--\>1,024                 512   \>1,024             5 (13.5)   19 (51)   0
  France, hospital isolates resistant to ampicillin and cotrimoxazole (100)   32--\>1,024                 64    \>1,024             1 (1)      13 (13)   0

*\**ESBL, extended-spectrum β-lactamase; MIC~50~, MIC at which 50% of isolates are inhibited; MIC~90~, MIC at which 90% of isolates are inhibited. †No isolate contained the *erm*(A), *erm*(C), *ere*(A), *ere*(B), *msr*(A), or *mef*(A) genes.
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MICs differed according to the origin of the isolates. Multiple resistance was associated with MICs of erythromycin \>256 mg/L with 1 exception: an isolate from Guiana was resistant only to amoxicillin and cotrimoxazole (MIC of erythromycin, 1,024 mg/L).

We screened for macrolide resistance genes by using oligonucleotide primers and PCR conditions ([Table 2](#T2){ref-type="table"}). PCR reactions were performed as follows: an initial denaturation step (95^o^C, 3 min) followed by 30 cycles consisting of denaturation (95^o^C, 30 s), annealing at a temperature depending on the primers used (30 s), elongation (72^o^C, 30 s) and a final extension step (72^o^C, 10 min). Positive and negative controls were included in each run.

###### Oligonucleotide primers used for detection of *Escherichia coli* macrolide resistance genes

  Target gene   Primer   Sequence, 5′ → 3′           Product size, bp   Annealing temperature, ^o^C
  ------------- -------- --------------------------- ------------------ -----------------------------
  *mph*(A)      mphAF    GTGAGGAGGAGCTTCGCGAG        403                60
                mphAR    TGCCGCAGGACTCGGAGGTC                           
  *mph*(B)      mphBF    GATATTAAACAAGTAATCAGAATAG   494                58
                mphBR    GCTCTTACTGCATCCATACG                           
  *erm*(A)      ermAF    TCTAAAAAGCATGTAAAAGAAA      533                52
                ermAR    CGATACTTTTTGTAGTCCTTC                          
  *erm*(B)      ermBF    GAAAAAGTACTCAACCAAATA       639                45
                ermBR    AATTTAAGTACCGTTACT                             
  *erm*(C)      ermCF    TCAAAACATAATATAGATAAA       642                45
                ermCR    GCTAATATTGTTTAAATCGTCAAT                       
  *ere*(A)      ereAF    GCCGGTGCTCATGAACTTGAG       420                60
                ereAR    CGACTCTATTCGATCAGAGGC                          
  *ere*(B)      ereBF    TTGGAGATACCCAGATTGTAG       537                55
                ereBR    GAGCCATAGCTTCAACGC                             
  *mef*(A)      mefAF    AGTATCATTAATCACTAGTGC       345                54
                mefAR    TTCTTCTGGTACTAAAAGTGG                          
  *msr*(A)      msrAF    GCACTTATTGGGGGTAATGG        384                58
                msrAR    GTCTATAAGTGCTCTATCGTG                          

The *mph*(A) gene was commonly present in 34 isolates (MICs 256 mg/L to \>1,024 mg/L). The gene was mostly detected in isolates resistant to cefotaxime (27 isolates) but also in 4 (21%) of 19 isolates resistant to only amoxicillin and cotrimoxazole in different countries. To confirm this latter association, we searched for the *mph*(A) gene in 100 clinical isolates of *E. coli* from the Caen hospital coresistant to amoxicillin and cotrimoxazole but susceptible to cefotaxime, which is a common phenotype present in ≈25% of *E. coli* isolates from this hospital. The gene was detected in 13 isolates (MIC \>256 mg/L), confirming the presence of the gene in non--multidrug-resistant *E. coli* ([Table 1](#T1){ref-type="table"}). In a previous study on the distribution of 7 macrolide resistance genes in gram-negative isolates from the urine and oral cavity of healthy children in Portugal, Ojo et al. detected the *mph*(A) gene in 15 of 26 studied *E. coli* isolates ([@R10]). However, the profile of resistance to other antimicrobial drugs was not determined.

The other macrolide resistance genes were more scarce. The *erm*(B) gene was detected in 2 isolates (MICs \>1,024 mg/L) and *mph*(B) in 2 others (MICs 128 mg/L). In 4 isolates (MICs \>1,024 mg/L), both *mph*(A) and *erm*(B) were amplified. The 6 other genes, *erm*(A), *erm*(C), *ere*(A), *ere*(B), *mef*(A), and *msr*(A), were not detected. In 6 isolates with MICs of erythromycin equal to 256 mg/L and 2 with MICs of erythromycin equal to 512 mg/L, no resistance gene could be amplified, suggesting the presence of other macrolide resistance determinants. Distribution of the resistance genes *mph*(A), *erm*(B), and *mph*(B) is shown in [Table 1](#T1){ref-type="table"} and in the Figure.

Conclusions
===========

The plasmid-borne *mph*(A) gene detected in *S. sonnei* resistant to azithromycin was the most common macrolide resistance gene detected in *E. coli* collected in 5 countries on 4 continents. The gene was mostly detected in isolates from patients who had received antimicrobial drugs or had been hospitalized, in particular in ESBL producers, but was also detected in *E. coli* isolates coresistant to amoxicillin and cotrimoxazole, which are common worldwide. Because *E. coli* and *Shigella* spp. are phylogenetically closely related species that easily exchange plasmids, further dissemination of resistance to macrolides in the latter species may be predicted. Also, plasmid-mediated resistance to macrolides may emerge in *Salmonella* spp., which is also a target of azithromycin.
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